



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

| APPLICATION NO. | FILING DATE | FIRST NAMED INVENTOR | ATTORNEY DOCKET NO. | CONFIRMATION NO. |
|--|-------------|----------------------|---------------------|------------------|
| 10/011,011 | 11/19/2001 | Francisco Sureda | 14XZ00088 | 7584 |
| 23413 | 7590 | 10/17/2006 | EXAMINER | |
| CANTOR COLBURN, LLP 55 GRIFFIN ROAD SOUTH BLOOMFIELD, CT 06002 | | | ALHIJA, SAIF A | |
| | | | ART UNIT | PAPER NUMBER |
| | | | 2128 | |

DATE MAILED: 10/17/2006

Please find below and/or attached an Office communication concerning this application or proceeding.

| | | | |
|------------------------------|------------------------|---------------------|--|
| Office Action Summary | Application No. | Applicant(s) | |
| | 10/011,011 | SUREDA ET AL. | |
| | Examiner | Art Unit | |
| | Saif A. Alhija | 2128 | |

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 06 September 2006.
- 2a) ☒ This action is **FINAL**. 2b) ☐ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 2-57 and 59-63 is/are pending in the application.
- 4a) Of the above claim(s) _____ is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☒ Claim(s) 2-57 and 59-63 is/are rejected.
- 7) ☐ Claim(s) _____ is/are objected to.
- 8) ☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☒ The drawing(s) filed on 19 November 2002 is/are: a) ☒ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☒ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☒ All b) ☐ Some * c) ☐ None of:
1. ☒ Certified copies of the priority documents have been received.
 2. ☐ Certified copies of the priority documents have been received in Application No. _____.
 3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- | | |
|--|---|
| 1) <input checked="" type="checkbox"/> Notice of References Cited (PTO-892) | 4) <input type="checkbox"/> Interview Summary (PTO-413) |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) | Paper No(s)/Mail Date: _____ |
| 3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO/SB/08) | 5) <input type="checkbox"/> Notice of Informal Patent Application |
| Paper No(s)/Mail Date: _____ | 6) <input type="checkbox"/> Other: _____ |

DETAILED ACTION

1. Claims 2-57, and 59-63 have been presented for examination.

Response to Arguments

2. Applicant's arguments filed 6 September 2006 have been fully considered but they are not persuasive.

- i) Following Applicants amendment the 112 2nd rejections have been withdrawn.
- ii) Following Applicants amendment the 101 rejections have been withdrawn.
- iii) Applicant argues that the reference does not disclose "superimposing the deployed three dimensional image of the prosthesis and the three dimensional image of the lesion to provide a combined three-dimensional image to visualize the interaction or involvement between the lesion and the deployed prosthesis." The reference discloses underneath Figure 8, for example, **"finite element modeling of the balloon positioned within the lumen of the stenosis and then inflated against a virtual blocked vessel."** It is unclear how this statement and the corresponding figures 8-10 do not anticipate the invention conceptually, and from a patentable distinction point of view. The superimposing of 2 three-dimensional images of a prosthesis and a lesion is shown in the figures and its implementation and virtual testing are discussed.
- iv) The Applicant further argues that the reference does not solve the problem of "predicting the result of an endovascular procedure and seeking a method to provide the operator in choosing an endovascular prosthesis or a deployment technique." First these statements appear to be intended use. Second, it is unclear how the statement provided in Section 2.iii above does not address these problems.
- v) The amendments regarding storage are also anticipated since the reference's software is run on a computer, see FEM model in Figures 8-10.
- vi) The Applicant argues the Examiner may be using hindsight analysis with regards to anticipation by the reference. It is noted that hindsight analysis is not relevant for a 102 rejection.

Claim Objections

3. Claims 60-63 are objected to under 37 CFR 1.75(c), as being of improper dependent form for failing to further limit the subject matter of a previous claim. Applicant is required to cancel the claim(s), or amend the claim(s) to place the claim(s) in proper dependent form, or rewrite the claim(s) in independent form.

Claims 60-63 comprise an article of manufacture, program storage device, and computer program product. These do not appear to be proper product by process claims. The claims are dependent upon a method. This represents a mixing of statutory classes and as such the claims do not further limit the parent claim.

Claim Rejections - 35 USC § 101

35 U.S.C. 101 reads as follows:

Whoever invents or discovers any new and useful process, machine, manufacture, or composition of matter, or any new and useful improvement thereof, may obtain a patent therefor, subject to the conditions and requirements of this title.

MPEP 2106 recites:

The claimed invention as a whole must accomplish a practical application. That is, it must produce a "useful, concrete and tangible result" State Street 149 F.3d at 1373, 47 USPQ2d at 1601-02. A process that consists solely of the manipulation of an abstract idea is not concrete or tangibles. See *In re Warmerdam*, 33 F.3d 1354, 1360, 31 USPQ2d 1754, 1759 (Fed.Cir. 1994). See also *Schrader*, 22 F.3d at 295, 30 USPQ2d at 1459.

4. **Claims 60-63 are rejected** under 35 U.S.C. 101 because the claimed invention is directed to non-statutory subject matter.

Claims 60-63 comprise an article of manufacture, program storage device, and computer program product. However the claims are dependent upon a method. This represents a mixing of statutory classes and as such the claims are non-statutory.

Art Unit: 2128

Appropriate correction is required.

All claims dependent upon a rejected base claim are rejected by virtue of their dependency.

Claim Rejections - 35 USC § 112

The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

5. **Claims 2-56 and 59-63 are rejected** under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

Claim 59 recites determining a model or parametric characteristics. However the dependent claims elaborate only on the model disclosed. This would render the claims vague and indefinite.

Appropriate correction is required.

All claims dependent upon a rejected base claim are rejected by virtue of their dependency.

Claim Rejections - 35 USC § 102

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless –

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

6. **Claims 2-57, and 59-63 are rejected** under 35 U.S.C. 102(b) as being clearly anticipated by **Haridas et al, Medical Device and Diagnostic Industry Magazine “Predictive Analysis at the Forefront of Medical Product Development”**, hereafter referred to as **Haridas**.

Regarding Claim 2:

Haridas discloses Method according to claim 59, wherein the two three-dimensional images comprise a first three-dimensional simulated image showing the endovascular prosthesis deployed, taking into account the resistance of the lesion, and a second three-dimensional simulated image showing the enlarged lesion following the deployment of the endovascular prosthesis. **(Page 4, “What If” Material Sensitivity Studies. Page 6, Figure 8)**

Regarding Claim 3:

Haridas discloses Method according to claim 2, wherein the first three-dimensional simulated image showing the endovascular prosthesis deployed is obtained from a model of the implant. **(Page 4, “What If” Material Sensitivity Studies. Page 6, Figure 8)**

Regarding Claim 4:

Haridas discloses Method according to claim 3, wherein the model of the implant is obtained from the mechanical characteristics of the prosthesis or from characteristics of the prosthesis and a three-dimensional image of the contracted prosthesis. **(Page 4, “What If” Material Sensitivity Studies. Page 6, Figure 8)**

Regarding Claim 5:

Haridas discloses Method according to one of claim 2, wherein the second three-dimensional simulated image showing the enlarged lesion is obtained from a model of the lesion. **(Page 4, “What If” Material Sensitivity Studies. Page 6, Figure 8)**

Regarding Claim 6:

Haridas discloses Method according to one of claim 3, wherein the second three-dimensional simulated image showing the enlarged lesion is obtained from a model of the lesion. (Page 4, “What If” Material Sensitivity Studies. Page 6, Figure 8)

Regarding Claim 7:

Haridas discloses Method according to one of claim 4, wherein the second three-dimensional simulated image showing the enlarged lesion is obtained from a model of the lesion. (Page 4, “What If” Material Sensitivity Studies. Page 6, Figure 8)

Regarding Claim 8:

Haridas discloses Method according to claim 2, wherein the model of the lesion is obtained from the composition and biomechanical properties of the blood vessels and surrounding atheromatous plaques and from a three-dimensional image of the lesion. (Page 6, Paragraph 2)

Regarding Claim 9:

Haridas discloses Method according to claim 3, wherein the model of the lesion is obtained from the composition and biomechanical properties of the blood vessels and surrounding atheromatous plaques and from a three-dimensional image of the lesion. (Page 6, Paragraph 2)

Regarding Claim 10:

Haridas discloses Method according to claim 4, wherein the model of the lesion is obtained from the composition and biomechanical properties of the blood vessels and surrounding atheromatous plaques and from a three-dimensional image of the lesion. (Page 6, Paragraph 2)

Regarding Claim 11:

Haridas discloses Method according to claim 5, wherein the model of the lesion is obtained from the composition and biomechanical properties of the blood vessels and surrounding atheromatous plaques and from a three-dimensional image of the lesion. **(Page 6, Paragraph 2)**

Regarding Claim 12:

Haridas discloses Method according to claim 3, wherein, for particular parameters concerning the deployment technique, the lesion and the vascular prosthesis, the biomechanical properties of the lesion are taken into account to execute the model of the prosthesis in order to obtain a three-dimensional image of the prosthesis deployed, and then to execute the model of the lesion in order to obtain a three-dimensional image of the enlarged lesion. **(Page 6, Paragraphs 1-2)**

Regarding Claim 13:

Haridas discloses Method according to claim 4, wherein, for particular parameters concerning the deployment technique, the lesion and the vascular prosthesis, the biomechanical properties of the lesion are taken into account to execute the model of the prosthesis in order to obtain a three-dimensional image of the prosthesis deployed, and then to execute the model of the lesion in order to obtain a three-dimensional image of the enlarged lesion. **(Page 6, Paragraphs 1-2)**

Regarding Claim 14:

Haridas discloses Method according to claim 5, wherein, for particular parameters concerning the deployment technique, the lesion and the vascular prosthesis, the biomechanical properties of the lesion are taken into account to execute the model of the prosthesis in order to obtain a three-dimensional

Art Unit: 2128

image of the prosthesis deployed, and then to execute the model of the lesion in order to obtain a three-dimensional image of the enlarged lesion. **(Page 6, Paragraphs 1-2)**

Regarding Claim 15:

Haridas discloses Method according to claim 6, wherein, for particular parameters concerning the deployment technique, the lesion and the vascular prosthesis, the biomechanical properties of the lesion are taken into account to execute the model of the prosthesis in order to obtain a three-dimensional image of the prosthesis deployed, and then to execute the model of the lesion in order to obtain a three-dimensional image of the enlarged lesion. **(Page 6, Paragraphs 1-2)**

Regarding Claim 16:

Haridas discloses Method according to claim 7, wherein, for particular parameters concerning the deployment technique, the lesion and the vascular prosthesis, the biomechanical properties of the lesion are taken into account to execute the model of the prosthesis in order to obtain a three-dimensional image of the prosthesis deployed, and then to execute the model of the lesion in order to obtain a three-dimensional image of the enlarged lesion. **(Page 6, Paragraphs 1-2)**

Regarding Claim 17:

Haridas discloses Method according to claim 8, wherein, for particular parameters concerning the deployment technique, the lesion and the vascular prosthesis, the biomechanical properties of the lesion are taken into account to execute the model of the prosthesis in order to obtain a three-dimensional image of the prosthesis deployed, and then to execute the model of the lesion in order to obtain a three-dimensional image of the enlarged lesion. **(Page 6, Paragraphs 1-2)**

Regarding Claim 18:

Haridas discloses Method according to claim 9, wherein, for particular parameters concerning the deployment technique, the lesion and the vascular prosthesis, the biomechanical properties of the lesion are taken into account to execute the model of the prosthesis in order to obtain a three-dimensional image of the prosthesis deployed, and then to execute the model of the lesion in order to obtain a three-dimensional image of the enlarged lesion. **(Page 6, Paragraphs 1-2)**

Regarding Claim 19:

Haridas discloses Method according to claim 10, wherein, for particular parameters concerning the deployment technique, the lesion and the vascular prosthesis, the biomechanical properties of the lesion are taken into account to execute the model of the prosthesis in order to obtain a three-dimensional image of the prosthesis deployed, and then to execute the model of the lesion in order to obtain a three-dimensional image of the enlarged lesion. **(Page 6, Paragraphs 1-2)**

Regarding Claim 20:

Haridas discloses Method according to claim 3, wherein the model of the prosthesis is established as a function of the radial pressure and resistance forces on the mesh of the prosthesis. **(Page 5, Paragraph 1. Figure 7)**

Regarding Claim 21:

Haridas discloses Method according to claim 4, wherein the model of the prosthesis is established as a function of the radial pressure and resistance forces on the mesh of the prosthesis. **(Page 5, Paragraph 1. Figure 7)**

Regarding Claim 22:

Haridas discloses Method according to claim 5, wherein the model of the prosthesis is established as a function of the radial pressure and resistance forces on the mesh of the prosthesis. **(Page 5, Paragraph 1. Figure 7)**

Regarding Claim 23:

Haridas discloses Method according to claim 6, wherein the model of the prosthesis is established as a function of the radial pressure and resistance forces on the mesh of the prosthesis. **(Page 5, Paragraph 1. Figure 7)**

Regarding Claim 24:

Haridas discloses Method according to claim 7, wherein the model of the prosthesis is established as a function of the radial pressure and resistance forces on the mesh of the prosthesis. **(Page 5, Paragraph 1. Figure 7)**

Regarding Claim 25:

Haridas discloses Method according to claim 8, wherein the model of the prosthesis is established as a function of the radial pressure and resistance forces on the mesh of the prosthesis. **(Page 5, Paragraph 1. Figure 7)**

Regarding Claim 26:

Haridas discloses Method according to claim 9, wherein the model of the prosthesis is established as a function of the radial pressure and resistance forces on the mesh of the prosthesis. **(Page**

Art Unit: 2128

5, Paragraph 1. Figure 7)

Regarding Claim 27:

Haridas discloses Method according to claim 10, wherein the model of the prosthesis is established as a function of the radial pressure and resistance forces on the mesh of the prosthesis. **(Page 5, Paragraph 1. Figure 7)**

Regarding Claim 28:

Haridas discloses Method according to claim 11, wherein the model of the prosthesis is established as a function of the radial pressure and resistance forces on the mesh of the prosthesis. **(Page 5, Paragraph 1. Figure 7)**

Regarding Claim 29:

Haridas discloses Method according to claim 12, wherein the model of the prosthesis is established as a function of the radial pressure and resistance forces on the mesh of the prosthesis. **(Page 5, Paragraph 1. Figure 7)**

Regarding Claim 30:

Haridas discloses Method according to claim 13, wherein the model of the prosthesis is established as a function of the radial pressure and resistance forces on the mesh of the prosthesis. **(Page 5, Paragraph 1. Figure 7)**

Regarding Claim 31:

Haridas discloses Method according to claim 14, wherein the model of the prosthesis is established as a function of the radial pressure and resistance forces on the mesh of the prosthesis. **(Page 5, Paragraph 1. Figure 7)**

Regarding Claim 32:

Haridas discloses Method according to claim 15, wherein the model of the prosthesis is established as a function of the radial pressure and resistance forces on the mesh of the prosthesis. **(Page 5, Paragraph 1. Figure 7)**

Regarding Claim 33:

Haridas discloses Method according to claim 16, wherein the model of the prosthesis is established as a function of the radial pressure and resistance forces on the mesh of the prosthesis. **(Page 5, Paragraph 1. Figure 7)**

Regarding Claim 34:

Haridas discloses Method according to claim 17, wherein the model of the prosthesis is established as a function of the radial pressure and resistance forces on the mesh of the prosthesis. **(Page 5, Paragraph 1. Figure 7)**

Regarding Claim 35:

Haridas discloses Method according to claim 18, wherein the model of the prosthesis is established as a function of the radial pressure and resistance forces on the mesh of the prosthesis. **(Page 5, Paragraph 1. Figure 7)**

Art Unit: 2128

Regarding Claim 36:

Haridas discloses Method according to claim 5, wherein the model of the lesion is established by means of the finite-element method. **(Page 5, Paragraph 1. Figure 7)**

Regarding Claim 37:

Haridas discloses Method according to claim 6, wherein the model of the lesion is established by means of the finite-element method. **(Page 5, Paragraph 1. Figure 7)**

Regarding Claim 38:

Haridas discloses Method according to claim 7, wherein the model of the lesion is established by means of the finite-element method. **(Page 5, Paragraph 1. Figure 7)**

Regarding Claim 39:

Haridas discloses Method according to claim 8, wherein the model of the lesion is established by means of the finite-element method. **(Page 5, Paragraph 1. Figure 7)**

Regarding Claim 40:

Haridas discloses Method according to claim 9, wherein the model of the lesion is established by means of the finite-element method. **(Page 5, Paragraph 1. Figure 7)**

Regarding Claim 41:

Haridas discloses Method according to claim 10, wherein the model of the lesion is established by means of the finite-element method. **(Page 5, Paragraph 1. Figure 7)**

Regarding Claim 42:

Haridas discloses Method according to claim 11, wherein the model of the lesion is established by means of the finite-element method. **(Page 5, Paragraph 1. Figure 7)**

Regarding Claim 43:

Haridas discloses Method according to claim 12, wherein the model of the lesion is established by means of the finite-element method. **(Page 5, Paragraph 1. Figure 7)**

Regarding Claim 44:

Haridas discloses Method according to claim 13, wherein the model of the lesion is established by means of the finite-element method. **(Page 5, Paragraph 1. Figure 7)**

Regarding Claim 45:

Haridas discloses Method according to claim 14, wherein the model of the lesion is established by means of the finite-element method. **(Page 5, Paragraph 1. Figure 7)**

Regarding Claim 46:

Haridas discloses Method according to claim 15, wherein the model of the lesion is established by means of the finite-element method. **(Page 5, Paragraph 1. Figure 7)**

Regarding Claim 47:

Haridas discloses Method according to claim 16, wherein the model of the lesion is established by means of the finite-element method. **(Page 5, Paragraph 1. Figure 7)**

Regarding Claim 48:

Haridas discloses Method according to claim 17, wherein the model of the lesion is established by means of the finite-element method. **(Page 5, Paragraph 1. Figure 7)**

Regarding Claim 49:

Haridas discloses Method according to claim 18, wherein the model of the lesion is established by means of the finite-element method. **(Page 5, Paragraph 1. Figure 7)**

Regarding Claim 50:

Haridas discloses Method according to claim 19, wherein the model of the lesion is established by means of the finite-element method. **(Page 5, Paragraph 1. Figure 7)**

Regarding Claim 51:

Haridas discloses Method according to claim 20, wherein the model of the lesion is established by means of the finite-element method. **(Page 5, Paragraph 1. Figure 7)**

Regarding Claim 52:

Haridas discloses Method according to claim 21, wherein the model of the lesion is established by means of the finite-element method. **(Page 5, Paragraph 1. Figure 7)**

Regarding Claim 53:

Haridas discloses Method according to claim 22, wherein the model of the lesion is established by means of the finite-element method. **(Page 5, Paragraph 1. Figure 7)**

Regarding Claim 54:

Haridas discloses Method according to claim 23, wherein the model of the lesion is established by means of the finite-element method. **(Page 5, Paragraph 1. Figure 7)**

Regarding Claim 55:

Haridas discloses Method according to claim 24, wherein the model of the lesion is established by means of the finite-element method. **(Page 5, Paragraph 1. Figure 7)**

Regarding Claim 56:

Haridas discloses Method according to claim 59, wherein on an effective deployment of the prosthesis in the lesion, the instantaneous state of the endovascular prosthesis and shape of the lesion are taken into account in order to simulate and visualize in three dimensions a future state of the endovascular prosthesis and of the lesion as a function of possible actions indicated by an operator. **(Page 4, “What If” Material Sensitivity Studies. Page 5, Paragraph 1. Page 6, Paragraphs 1-2. Figure 7-8)**

Regarding Claim 57:

Haridas discloses A system to simulate the diameter enlargement of a lesion of a blood vessel comprising:

means for providing an endovascular prosthesis; means for providing a computer equipped with data storage; means for processing and display; **(Page 4, “What If” Material Sensitivity Studies. Page 5, Paragraph 1. Page 6, Paragraphs 1-2. Figure 7-8)**

means for visualizing a three-dimensional simulated image showing the result of interaction between the lesion and the endovascular prosthesis after deployment of the prosthesis, the three-

Art Unit: 2128

dimensional simulated image being obtained by superposition of two three-dimensional images; (**Page 4, “What If” Material Sensitivity Studies. Page 5, Paragraph 1. Page 6, Paragraphs 1-2. Figure 7-8)**

and the means for providing a computer being optionally connected to a means for display. (**Page 4, “What If” Material Sensitivity Studies. Page 5, Paragraph 1. Page 6, Paragraphs 1-2. Figure 7-8)**

Regarding Claim 58:

Haridas discloses A computer data storage means comprising a computer program, which enables a computer to execute:

the procedure of synthesis of the model of an endovascular prosthesis and of the model of a lesion of a blood vessel in order to simulate the interaction between the lesion and the endovascular prosthesis after deployment of the latter, and the procedure of display on a screen of a three-dimensional simulated image showing the result of the interaction. (**Page 4, “What If” Material Sensitivity Studies. Page 5, Paragraph 1. Page 6, Paragraphs 1-2. Figure 7-8)**

Regarding Claim 59:

Haridas discloses a method for simulating the diameter enlargement of a lesion of a blood vessel by means of an endovascular prosthesis comprising,

Determining a model or parametric characteristic of a lesion; (**Page 4, “What If” Material Sensitivity Studies. Page 6, Figure 8)**

creating a three-dimensional image of the lesion from the model or parametric characteristics; (**Page 4, “What If” Material Sensitivity Studies. Page 6, Figure 8)**

determining a model or parametric characteristics of the prosthesis when in a non-deployed stated; (**Page 4, “What If” Material Sensitivity Studies.**

Art Unit: 2128

Page 6, Figure 8)

creating a three dimensional image of the prosthesis from the model or parametric characteristics;

(Page 4, “What If” Material Sensitivity Studies.

Page 6, Figure 8)

deploying the prosthesis into the blood vessel; and **(Page 4, “What If” Material Sensitivity**

Studies. Page 6, Figure 8)

superimposing the deployed three dimensional image of the prosthesis and the three dimensional

image of the lesion to provide a combined three-

dimensional image to visualize the interaction or involvement between the lesion and the deployed

prosthesis. **(Page 4, “What If” Material Sensitivity Studies. Page 6, Figure 8)**

Regarding Claim 60:

Haridas discloses A computer program embodied in a computer readable medium comprising program code for implementing the method when the program code is read by a computer according to claim 59. **(Page 4, “What If” Material Sensitivity Studies. Page 5, Paragraph 1. Page 6, Paragraphs 1-2. Figure 7-8)**

Regarding Claim 61:

Haridas discloses A computer program product comprising a computer useable medium having computer readable program code embodied in the medium, the computer readable program code implementing the method according to claim 59 when the program is executed by a computer. **(Page 4, “What If” Material Sensitivity Studies. Page 5, Paragraph 1. Page 6, Paragraphs 1-2.**

Figure 7-8)

Art Unit: 2128

Regarding Claim 62:

Haridas discloses An article of manufacture for use with a computer system, the article of manufacture comprising a computer readable medium having computer readable program code embodied in the medium, the program code implementing the method according to claim 59 when the program is read by the system. (Page 4, "What If" Material Sensitivity Studies. Page 5, Paragraph 1. Page 6, Paragraphs 1-2. Figure 7-8)

Regarding Claim 63:

Haridas discloses A program storage device readable by a processor tangibly embodying a program of instructions executable by the processor to perform the method according to claim 59. (Page 4, "What If" Material Sensitivity Studies. Page 5, Paragraph 1. Page 6, Paragraphs 1-2. Figure 7-8)

Conclusion

7. Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, **THIS ACTION IS MADE FINAL**. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the date of this final action.

8. All Claims are rejected.


Art Unit: 2128

9. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Saif A. Alhija whose telephone number is (571) 272-8635. The examiner can normally be reached on M-F, 11:00-7:30.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Kamini Shah can be reached on (571) 272-22792279. The fax phone number for the organization where this application or proceeding is assigned is (571) 273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

SAA
October 13, 2006


HUGH JONES Ph.D.
PATENT EXAMINER
EBC CENTER 2100